India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln

Investing.comMar 10, 2025 3:16 AM

View all comments（0）



Investing.com-- Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NSE:SUN) said on Monday that it will buy Checkpoint Therapeutics Inc (NASDAQ:CKPT)- a Nasdaq-listed immunotherapy and oncology firm- for about $355 million.

Sun said it will offer $4.10 in cash for each share in Checkpoint, a nearly 66% premium to Checkpoint’s Friday close of $2.470. Checkpoint shareholders will also receive a commitment for an additional $0.70 per share if the company’s cosbelimab treatment is approved in Europe prior to certain deadlines.

Cosibelimab- which is Checkpoint’s FDA-approved treatment for certain variants of skin cancer- is the key motivator behind Sun’s bid, with the Indian pharmaceutical firm stating that the deal will introduce Checkpoint’s treatment across more countries.

The deal is expected to be completed in the second quarter of 2025.

Sun has also entered into a royalty agreement with Fortress Biotech Inc (NASDAQ:FBIO), Checkpoint’s controlling shareholder, under which the latter will receive payments based on future sales of cosibelimab.

Sun Pharma was founded in 1983 and is one of the world’s biggest manufacturers of generic pharmaceuticals, which are also a major export product for India. The company has diversified into a wide range of healthcare services in recent years, and offers services in over 100 countries.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

KOSPI Crosses 6,000 as Kioxia Soars Nearly 14%, SK Hynix Jumps 11%, Samsung Rallies Over 9%

The KOSPI surged 6.63%, breaching the 6,000-point mark, as SK Hynix rallied 11%, Kioxia soared nearly 14%, and Samsung and SoftBank joined the rally.

SK Hynix Surges Over 4% as Q3 Results Hit Record High, Returning $75 Billion to Shareholders

SK Hynix reported a record-breaking Q3 operating profit while announcing a massive 100 trillion won (approximately $75 billion) shareholder return plan, sending its stock price surging 4%.

KOSPI Tops 5,800, Kioxia Jumps Over 4% as SK Hynix Revenue and Profit Hit Record Highs

The KOSPI surged over 3%, Kioxia jumped 4%, Samsung and SoftBank joined the rally, and SK Hynix unveiled a massive 100 trillion KRW in shareholder returns.

US Stocks Close: Nasdaq Rises Over 1%, Philadelphia Semiconductor Index Gains Over 3%; Chip Stocks Extend Rally, CoreWeave Gains Nearly 8%

On Tuesday, October 27, Eastern Time, U.S. stocks moved higher, with chip stocks extending their rally to drive the Nasdaq to lead the gains. Amid falling oil prices, investors continued to assess a heavy slate of corporate earnings reports while focusing on the Federal Reserve's interest rate meeting. At the close, the Dow Jones Industrial Average rose 0.03% to 52,377.57 points; the Nasdaq Composite Index gained 1.18% to 26,477.81 points; and the S&P 500 Index advanced 0.60% to 7,722.60 points.

Amazon Q3 Earnings Preview: AWS Growth Expected to Rise to 41%, Wall Street Top Price Target $400

TradingKey - Amazon (AMZN) will release its third-quarter 2026 financial results after the U.S. market close on October 29, Eastern Time, and hold an earnings conference call at 17:00 on the same day.

Featured Tools